Our findings show that C2 domain overexpressionprofoundly alters cell viability, apoptosis, and treatment sensitivity,highlighting its substantial contribution to PKC-δ activity.Targeting PKC-δ at the C2 domain level, or exploiting the isolateddomain as a pharmacological agent, may present novel therapeutic opportunitiesin BC. Here, PRKCD is linked to breast cancer.